Unknown

Dataset Information

0

DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.


ABSTRACT: Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ideal target for next generation of anti-inflammatory drugs without the side effects of currently available anti-inflammatory drugs. However, there has been no clinically promising mPGES-1 inhibitor identified through traditional drug discovery and development route. Here we report a new approach, called DREAM-in-CDM (Drug Repurposing Effort Applying Integrated Modeling-in vitro/vivo-Clinical Data Mining), to identify an FDA-approved drug suitable for use as an effective analgesic targeting mPGES-1. The DREAM-in-CDM approach consists of three steps: computational screening of FDA-approved drugs; in vitro and/or in vivo assays; and clinical data mining. By using the DREAM-in-CDM approach, lapatinib has been identified as a promising mPGES-1 inhibitor which may have significant anti-inflammatory effects to relieve various forms of pain and possibly treat various inflammation conditions involved in other inflammation-related diseases such as the lung inflammation caused by the newly identified COVID-19. We anticipate that the DREAM-in-CDM approach will be used to repurpose FDA-approved drugs for various new therapeutic indications associated with new targets.

SUBMITTER: Zhou S 

PROVIDER: S-EPMC7311425 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.

Zhou Shuo S   Zhou Ziyuan Z   Ding Kai K   Yuan Yaxia Y   Loftin Charles C   Zheng Fang F   Zhan Chang-Guo CG  

Scientific reports 20200623 1


Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ideal target for next generation of anti-inflammatory drugs without the side effects of currently available anti-inflammatory drugs. However, there has been no clinically promising mPGES-1 inhibitor identified through traditional drug discovery and development route. Here we report a new approach, called DREAM-in-CDM (Drug Repurposing Effort Applying Integrated Modeling-in vitro/vivo-Clinical Data Mining), to identify an FDA-approve  ...[more]

Similar Datasets

| S-EPMC5979965 | biostudies-literature
| S-EPMC7236256 | biostudies-literature
| S-EPMC8090911 | biostudies-literature
| S-EPMC3556848 | biostudies-other
| S-EPMC2095110 | biostudies-other
| S-EPMC7177823 | biostudies-literature
| S-EPMC3517626 | biostudies-literature
| S-EPMC2891414 | biostudies-literature
2018-01-01 | GSE85333 | GEO
| S-EPMC4142727 | biostudies-literature